A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment

Neurol Sci. 2022 Sep;43(9):5185-5187. doi: 10.1007/s10072-022-06108-6. Epub 2022 May 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19* / complications
  • Humans
  • Myasthenia Gravis* / complications
  • Myasthenia Gravis* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • eculizumab